APH-0912 / Aphios - LARVOL DELTA

A 62-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer - Episode 7: Approaching Systemic Therapy for mCRPC (Targeted Oncology) - "Tomasz M. Beer, MD, FACP: The question is about the broad range of options of metastatic castration-resistant prostate cancer in terms of systemic therapy. Here, we have a series of drugs that have been FDA approved based on an overall survival advantage. In terms of drugs that are molecularly unselected, I think about sipuleucel-T immunotherapy, enzalutamide and abiraterone for metastatic disease, docetaxel, cabazitaxel, and radium-223 dichloride."

Regulatory • Video